The European ADVANCE(CAT) project has taken its first steps. The final objective of the programme is to develop medicinal products for human use, from preclinical phases to their clinical application, based on genes (gene therapy), cells (cell therapy) and tissues (tissue engineering), i.e. the development of advanced therapies.
In their first quarterly work meeting, which took place in Barcelona on 1-2 February, the main aim was to examine the early work carried out and to plan the future actions of the project.
The leaders of the different work groups shared the tasks they have already completed and the challenges to be faced over the months before the next quarterly meeting. Each partner gave their six-month vision of forthcoming activities. A new website was announced, and the beginning of the activities on social networks.
ADVANCE(CAT) aims to develop medicinal products for human use with advanced therapies
The members attending the meeting conveyed their enthusiasm to the other collaborators about their involvement in the project. They asked questions and made proposals that are bound to help with the difficulties and risks that may ensue from a project of such magnitude.
La BMF forms part of the ADVANCE(CAT) European project, together with the Universitat de Barcelona (UB), Ferrer Internacional (Ferrer), the Banc de Sang i Teixits (BST), the Leitat Foundation, Bioiberica, the Centre de Medicina Regenerativa de Barcelona (CMRB), the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), the Fundació Bosch i Gimpera (FBiG) and the Fundació Institut d’Investigacions en Ciències de la Salut Germans Trias i Pujol (IGTP).
ADVANCE(CAT) is cofunded by the Catalonia Trade & Investment Agency (ACCIÓ), Generalitat de Catalunya, and the European Union in the FEDER Catalunya 2014-2020 framework.